Semiconductor conference to debut in Sydney

|

Published 14-MAY-2019 16:24 P.M.

|

3 minute read

Hey! Looks like you have stumbled on the section of our website where we have archived articles from our old business model.

In 2019 the original founding team returned to run Next Investors, we changed our business model to only write about stocks we carefully research and are invested in for the long term.

The below articles were written under our previous business model. We have kept these articles online here for your reference.

Our new mission is to build a high performing ASX micro cap investment portfolio and share our research, analysis and investment strategy with our readers.


Click Here to View Latest Articles

Pitt Street Research, in association with law firm Baker McKenzie, will host the inaugural Australian Semiconductor Conference in Sydney this week.

The conference will kick off at 8.45am on the 16th of May at Baker McKenzie’s office at Barangaroo Tower One. Professor Michelle Simmons, a leading quantum computer specialist from the UNSW and the 2018 Australian of the Year, will perform the keynote address.

Pitt Street Research is a leading ASX analyst that produces a variety of research reports on listed companies.

The conference is designed to familiarise willing investors with the semiconductor sector, which is largely unknown in broader circles.

The conference will feature several high profile ASX companies within the semiconductor space including – Sensera and 4DS Memory.

Sensera (ASX:SE1) is a leading developer of Micro Electro-Mechanical Systems (MEMS), which are miniature mechanical and electro-mechanical components.

These components are used to record real-world information such as acceleration, temperature, engine performance, flow of fluids plus more.

SE1 employs the use of semiconductor tech during the manufacturing process of its components, which can be integrated into various applications including military and electronics.

In addition, the company has made inroads into medical applications for microfluidic MEMS and Organ-on-a-Chip devices that can replicate and mimic functionality of human organs.

4DS Memory (ASX:4DS) has developed a tech called Interface Switching ReRAM (or resistive RAM), which could potentially replace NAND Flash memory, the most widely used form of RAM in devices today.

One of the key benefits behind ReRAM technology is its far higher data retention rate, which means it can retain a certain value far longer than the incumbent NAND tech. This should see marketable improvements in mobile battery life and reduce overhead costs for data centres and more.

4DS is now putting the finishing touches on its tech and will look to license the offering to a range of different semiconductor companies, which include tech giants Samsung and Intel.

Thanks to the inaugural Australian Semiconductor Conference, investors will be able to find out more about these two companies, as well as fellow industry leaders Bluechiip (ASX:BCT), Brainchip (ASX:BRN), Revasum (ASX:RVS), Audiopixels (ASX:AKP) and BluGlass (ASX:BLG).

“Here are seven quality companies that most will have not heard of or know much about,” Pitt Street Research’s Stuart Roberts said.

“Before too long a few could be worth more than the requisite A$2.1 billion or so that is required to be in the ASX200.”

RSVP to register your interest, seats are going fast. For those interested, email [email protected] or [email protected]

More about semiconductors

Semiconductor devices exploit the electronic properties of materials like silicon and germanium to function as the foundation of modern day electronics.

Semiconductor components are crucial in modern society, creating the foundation for everyday items such as mobile phones, computers, vehicles and more.

Now, a new breed of companies are pushing the boundaries of semiconductor tech to provide innovative cutting edge solutions in new frontier industries like biotech and renewable energy.



General Information Only

S3 Consortium Pty Ltd (S3, ‘we’, ‘us’, ‘our’) (CAR No. 433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information and is for informational purposes only. Any advice is general advice only. Any advice contained in this article does not constitute personal advice and S3 has not taken into consideration your personal objectives, financial situation or needs. Please seek your own independent professional advice before making any financial investment decision. Those persons acting upon information contained in this article do so entirely at their own risk.

Conflicts of Interest Notice

S3 and its associated entities may hold investments in companies featured in its articles, including through being paid in the securities of the companies we provide commentary on. We disclose the securities held in relation to a particular company that we provide commentary on. Refer to our Disclosure Policy for information on our self-imposed trading blackouts, hold conditions and de-risking (sell conditions) which seek to mitigate against any potential conflicts of interest.

Publication Notice and Disclaimer

The information contained in this article is current as at the publication date. At the time of publishing, the information contained in this article is based on sources which are available in the public domain that we consider to be reliable, and our own analysis of those sources. The views of the author may not reflect the views of the AFSL holder. Any decision by you to purchase securities in the companies featured in this article should be done so after you have sought your own independent professional advice regarding this information and made your own inquiries as to the validity of any information in this article.

Any forward-looking statements contained in this article are not guarantees or predictions of future performance, and involve known and unknown risks, uncertainties and other factors, many of which are beyond our control, and which may cause actual results or performance of companies featured to differ materially from those expressed in the statements contained in this article. S3 cannot and does not give any assurance that the results or performance expressed or implied by any forward-looking statements contained in this article will actually occur and readers are cautioned not to put undue reliance on forward-looking statements.

This article may include references to our past investing performance. Past performance is not a reliable indicator of our future investing performance.

 

Discover Small Cap
Biotech Stocks

Join thousands of other Investors following our stock commentary for Free

X